ReviewNature medicine2026
The science of psychedelic medicine.
Review in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Novel Tetrahydropyridinyl-6,6-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.ACS medicinal chemistry letters · 2026Article
- Psilocybin enhances sociability only in altered behavioural state and does not need an awake experience to be effective.Nature communications · 2026Article
- Psychedelic Safety and Clinical Outcomes Across Exposure Patterns: A Structured Narrative Review.Life (Basel, Switzerland) · 2026Review
- Novel Compounds as 5‑HT2A Agonists for Treating Mental Illness or CNS Disorders.ACS medicinal chemistry letters · 2026Article
- Novel 6,5-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.ACS medicinal chemistry letters · 2026Article
- Novel 5,6-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.ACS medicinal chemistry letters · 2026Article
- Synthesis and Biological Evaluation of 4‑Bromo-ACS omega · 2026Article
- Psychedelics relax predictive processing in the post-acute period by remodeling cortico-cortical feedback circuits.bioRxiv : the preprint server for biology · 2026Article
- Novel Tricyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.ACS medicinal chemistry letters · 2026Article
- Novel Indoline Derivatives Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness and CNS Disorders.ACS medicinal chemistry letters · 2026Article
- The renaissance of research on psychedelics in child and adolescent psychopharmacology.Child and adolescent psychiatry and mental health · 2026Article
- Systems-based psychiatry: insights from psychedelic research on mechanisms of healing.Frontiers in psychiatry · 2026Article
- On the meaning of "plasticity" in neuroscience and mental health research and its relation to the action of psychedelic therapy.Frontiers in neuroscience · 2026Article
- Disrupted synapses: prefrontal cortex-reward circuit dysfunction in stress-induced depression-like behaviors.Frontiers in cellular neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Classic psychedelics typically act at the serotonin 5-HT
Indexed as
Identifiers
41652120What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.